Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Post-operative Pain, Respiratory Depression
Interventions: Dexmedetomidine, Placebo (Normal Saline); Drug · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Participants
Interventions: AZD5462, Midazolam, Rosuvastatin, Digoxin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Chronic Intractable Pain
Interventions: Intraspinal Gabapentin; Drug
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 14
States / cities: Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more

Conditions: Hepatic Encephalopathy, Cirrhosis, Liver
Interventions: RBX7455, Placebo; Biological
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Jefferson, Louisiana

Conditions: Acute Mountain Sickness
Interventions: Prochlorperazine Maleate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Evergreen, Colorado

Conditions: Bleeding
Interventions: Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Advanced Solid Tumors
Interventions: DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP); Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 8
States / cities: San Diego, California • Jacksonville, Florida • Louisville, Kentucky + 5 more

Conditions: Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions: TTHX1114(NM141), Vehicle (placebo); Drug · Other
Lead sponsor: Trefoil Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more

Conditions: Type 2 Diabetes Mellitus
Interventions: BMF-219, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 36
States / cities: Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more

Conditions: Infra-orbital Hollows, Skin Quality Improvement
Interventions: RhPDGF-BB, Normal Saline; Biological · Drug
Lead sponsor: Lynch Regenerative Medicine; Network
Eligibility: 21 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Santa Monica, California • Chicago, Illinois + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo, BI1356 low dose, BI1356 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: San Antonio, Texas • Norfolk, Virginia

Conditions: Chronic Insomnia
Interventions: Low Dose Drug A, Low Dose Drug B, High Dose Drug A, High Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D, Placebo; Drug
Lead sponsor: Somnum Pharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Interventions: Sitagliptin; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
Interventions: FT538, Vorinostat; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2; Biological · Drug
Lead sponsor: David Bartlett, MD; Other
Eligibility: 18 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Safety
Interventions: PEP (Purified Exosome Product); Drug
Lead sponsor: Clinical Testing of Beverly Hills; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Encino, California

Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
Interventions: disitamab vedotin, tucatinib; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 77
States / cities: Tucson, Arizona • Orange, California • San Francisco, California + 39 more

Conditions: Chagas Disease
Interventions: Benznidazole, Placebo Oral Tablet; Drug
Lead sponsor: Tulane University School of Public Health and Tropical Medicine; Other
Eligibility: 13 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: San Diego, California • New Orleans, Louisiana

Conditions: Chronic Low-back Pain, Depression
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose); Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Human Immunodeficiency Virus, Chronic Neuropathic Pain
Interventions: Low Dose Naltrexone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Permanent Chemotherapy-induced Alopecia
Interventions: oral minoxidil; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overweight, Obesity
Interventions: AMG 133, Ondansetron; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Alamitos, California

Search by objective public record fields.

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

Islet Transplantation in Type 1 Diabetes

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

Phase 2 Evaluation of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Injection for the Treatment of Infraorbital Hollowing

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia

Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

Purified Exosome Product (PEP) Injected Into the Hypodermis

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

Psilocybin in Chronic Low Back Pain and Depression

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Low Dose Naltrexone for Pain in Patients With HIV

Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity